Supported by an educational grant from Merck
TITLE - Colorectal Cancer: Advances in Treatment & Management Strategies
TARGET AUDIENCE - Target audiences for this program are Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Oncology Pharmacists, Oncology Nurses, and Nurses
LEARNING OBJECTIVES - After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Oncology Pharmacists, Oncology Nurses, and Nurses
- Describe treatment options available for early- and late-stage colorectal cancer (CRC)
- Identify side effects associated with various treatment options available for CRC
- Discuss effective strategies for the management of treatment-related side effects with CRC therapies
- Recognize the prevalence of disease recurrence in patients with CRC
- Describe resistance mechanisms that can reduce patients' response to treatment in CRC, and identify combination therapies that may evade resistance
- Discuss disease and treatment-related education and guidance for patients to enhance engagement and decision-making
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/ services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by the Specialty Pharma Education Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Faculty Disclosure: Sonia Amin Thomas PharmD, BCOP, has no relevant conflicts of interest to disclose. She does not intend to discuss non-FDA approved drugs or investigational use of any product/device.
Pharmacist continuing education credit
Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test (score of 70% or higher). Participants will have 3 opportunities to pass the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Knowledge Based Activity
Course release date 9/16/2020
Course expires 9/16/2023
Nursing continuing education credit
Educational Review Systems is an approved provider of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Course release date: 9/19/2020
Course expires: 9/19/2022
|Activity Number||Credit Amount||Accreditation Period|
|0535-0000-20-008-H01-P||0.15 CEUs||September 16, 2020 - September 16, 2023|
|0535-0000-20-008-H01-N||1.5 hours of CNE||September 19, 2020 - September 19, 2022|